Revenue: As of FY2025 Q3, the actual value is USD 17.63 M.EPS: As of FY2025 Q3, the actual value is USD 0.11.EBIT: As of FY2025 Q3, the actual value is USD -4.805 M.<h3>Journey Medical Corporation (Journey)</h3><ul><li>Net Revenue: $17.6 million for the three months ended September 30, 2025, compared to $14.6 million for the same period in 2024.</li><li>Cost of Goods Sold: $5.8 million for the three months ended September 30, 2025, compared to $4.5 million for the same period in 2024.</li><li>Amortization of Acquired Intangible Assets: $1.1 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.</li><li>Research and Development Expenses: $0.3 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $12.1 million for the three months ended September 30, 2025, compared to $11.4 million for the same period in 2024.</li><li>Stock-Based Compensation - Selling, General and Administrative: $1.9 million for the three months ended September 30, 2025, compared to $1.5 million for the same period in 2024.</li></ul><h3>Avenue Therapeutics (Avenue)</h3><ul><li>Research and Development Expenses: $0.2 million for the three months ended September 30, 2025, compared to $2.3 million for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $0.5 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.</li><li>Stock-Based Compensation - Selling, General and Administrative: $0.1 million for the three months ended September 30, 2025, compared to $0.2 million for the same period in 2024.</li></ul><h3>Mustang Bio, Inc. (Mustang)</h3><ul><li>Research and Development Expenses: - $0.3 million for the three months ended September 30, 2025, compared to $0.1 million for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $1.0 million for the three months ended September 30, 2025, compared to $1.4 million for the same period in 2024.</li><li>Stock-Based Compensation - Selling, General and Administrative: $0.02 million for the three months ended September 30, 2025, compared to $0.05 million for the same period in 2024.</li></ul><h3>Fortress Biotech, Inc. (Fortress)</h3><ul><li>Research and Development Expenses: $0.1 million for the three months ended September 30, 2025, compared to - $0.1 million for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $3.9 million for the three months ended September 30, 2025, compared to $5.0 million for the same period in 2024.</li><li>Stock-Based Compensation - Selling, General and Administrative: $1.0 million for the three months ended September 30, 2025, compared to $2.5 million for the same period in 2024.</li></ul><h3>Consolidated</h3><ul><li>Net Revenue: $17.6 million for the three months ended September 30, 2025, compared to $14.6 million for the same period in 2024.</li><li>Cost of Goods Sold: $5.8 million for the three months ended September 30, 2025, compared to $4.5 million for the same period in 2024.</li><li>Amortization of Acquired Intangible Assets: $1.1 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024.</li><li>Research and Development Expenses: $0.2 million for the three months ended September 30, 2025, compared to $9.4 million for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $17.4 million for the three months ended September 30, 2025, compared to $22.0 million for the same period in 2024.</li><li>Stock-Based Compensation - Selling, General and Administrative: $3.0 million for the three months ended September 30, 2025, compared to $5.4 million for the same period in 2024.</li><li>Interest Income: $0.7 million for the three months ended September 30, 2025, compared to $0.6 million for the same period in 2024.</li><li>Interest Expense and Financing Fee: $2.7 million for the three months ended September 30, 2025, compared to $6.2 million for the same period in 2024.</li><li>Other Income: $17.7 million for the three months ended September 30, 2025, compared to $1.1 million for the same period in 2024.</li><li>Net Income (Loss) Attributable to Fortress: $5.9 million for the three months ended September 30, 2025, compared to - $12.9 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Journey Medical Corporation: Journey plans to continue expanding the payer coverage for Emrosi and other marketed products, focusing on increasing market penetration and sales.</li><li>Avenue Therapeutics: Avenue will focus on advancing its clinical development programs and exploring strategic partnerships to support its pipeline.</li><li>Mustang Bio, Inc.: Mustang will continue to streamline its operations, focusing on advancing its clinical programs and managing costs effectively.</li><li>Fortress Biotech, Inc.: Fortress will continue to leverage its expertise to support its subsidiaries and partner companies, exploring strategic arrangements to accelerate funding and development.</li></ul>

Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 10-Q: FY2025 Q3 Revenue: USD 17.63 M